lung
transplant
establish
treatment
option
select
patient
endstag
lung
diseas
chronic
lung
allograft
dysfunct
clad
infect
main
factor
limit
longterm
surviv
lung
transplant
recipi
ltr
acut
cellular
reject
acr
potenti
risk
factor
develop
clad
first
postop
year
acr
affect
ltr
least
necessit
treatment
steroid
augment
symptom
acr
nonspecif
includ
dyspnea
cough
sputum
product
fever
andor
hypoxia
noninvas
test
like
pulmonari
function
test
chest
imag
use
indic
potenti
complic
discriminatori
valu
acr
infect
reason
transbronchi
biopsi
tbb
remain
gold
standard
diagnosi
acr
howev
tbb
invas
bear
potenti
risk
pneumothorax
bleed
moreov
tbb
prone
sampl
error
interobserv
variabl
clinic
prognost
role
grade
acr
remain
unclear
depend
clinic
manag
guidelin
practic
standard
differ
transplant
center
find
grade
acr
might
ignor
prompt
repeat
biopsi
might
result
augment
immunosuppress
immens
work
multipl
laboratori
worldwid
current
way
determin
potenti
role
cytokin
diagnosi
treatment
monitor
diseas
progress
variou
field
heart
failur
neurodegener
gastrointestin
diseas
cytokin
product
bal
lymphocyt
mast
cell
shown
part
proand
antiinflammatori
process
lead
airflow
limit
exacerb
obstruct
lung
diseas
cytokin
furthermor
implic
reject
organ
transplant
induct
fibrot
pathway
acr
driven
cell
recognit
foreign
major
histocompat
complex
cytokin
play
key
role
process
stimul
prolifer
chemotaxi
activ
cytotox
lymphocyt
neutrophil
alveolar
macrophag
recent
review
potenti
role
surrog
marker
cytolog
cytokin
bronchoalveolar
lavag
bal
plasma
sampl
analyz
cytokin
bal
may
provid
inform
allograft
statu
potenti
use
diagnost
tool
advanc
detect
biomark
urgent
need
identifi
acr
reliabl
predict
increas
risk
develop
clad
retrospect
singlecent
studi
analyz
panel
proinflammatori
cytokin
includ
interleukin
il
interferongamma
tumor
necrosi
factor
alpha
larg
cohort
ltr
aim
studi
correl
cytokin
level
bal
fluid
surveil
bronchoscopi
develop
complic
includ
acr
infect
first
year
follow
lung
transplant
correl
might
provid
feasibl
specif
diagnost
potenti
allow
earli
recognit
subsequ
target
treatment
complic
ltr
start
four
cytokin
analyz
bal
fluid
ltr
surveil
bronchoscopi
futur
research
purpos
enrol
patient
whose
medic
record
includ
bal
cytokin
analys
concomitantli
obtain
tbb
well
microbiolog
studi
studi
approv
canton
ethic
committe
zurich
kekzh
number
gener
primari
ltr
univers
hospit
zurich
receiv
induct
therapi
antithymocyt
globulin
basiliximab
lifelong
tripl
immunosuppress
therapi
center
cyclosporin
taper
dose
prednison
azathioprin
mycophenol
mofetil
sinc
use
antiinfect
prophylaxi
use
previous
describ
patient
classifi
cytomegaloviru
cmv
intermediaterisk
highrisk
receiv
prophylaxi
valganciclovir
case
clad
macrolid
given
immunomodul
regular
interv
bal
fluid
tbb
obtain
routin
surveil
bronchoscopi
first
year
transplant
one
two
three
four
six
month
follow
lung
transplant
level
creactiv
protein
crp
routin
measur
patient
surveil
bronchoscopi
patient
undergo
surveil
bronchoscopi
clinic
unstabl
show
clinic
sign
infect
infectionassoci
lung
allograft
dysfunct
elev
inflammatori
marker
laboratori
bronchoscopi
perform
specif
clinic
indic
event
exclud
studi
lavag
perform
subsegment
bronchu
either
lingula
middl
lobe
use
three
four
ml
aliquot
salin
solut
five
eight
tbb
taken
lower
lobe
fixat
formaldehyd
solut
serial
section
biopsi
specimen
stain
hematoxylin
eosin
elast
van
gieson
grocott
bal
fluid
cytokin
concentr
determin
univers
hospit
zurich
immunolog
laboratori
use
commerci
avail
valid
quantit
sandwich
enzym
immunoassay
immunoassay
use
micropl
precoat
polyclon
antibodi
specif
cytokin
enzymelink
polyclon
antibodi
detect
blind
fashion
r
system
minneapoli
mn
usa
elisa
kit
includ
elisa
human
immunoassay
catalog
elisa
human
immunoassay
catalog
elisa
human
immunoassay
catalog
hs
elisa
human
immunoassay
catalog
cytokin
measur
accord
manufactur
instruct
absorb
measur
enzymelink
immunosorb
assay
elisa
reader
dynex
opsi
micropl
reader
nm
respect
cytokin
concentr
determin
interpol
standard
curv
express
pgml
sensit
assay
pgml
pgml
pgml
pgml
bal
fluid
cytokin
concentr
measur
week
bal
fluid
cytokin
sampl
store
process
maximum
one
week
start
sampl
centrifug
min
speed
g
immedi
prior
measur
supernat
remov
pellet
centrifug
summari
assay
diluent
ad
well
cytokin
micropl
well
respect
bal
sampl
standard
control
ad
suggest
manufactur
incub
h
h
plate
wash
four
time
five
time
six
time
remov
excess
liquid
wash
thoroughli
essenti
henc
plate
wash
suggest
provid
respect
conjug
ad
incub
room
temperatur
one
hour
two
hour
plate
wash
four
time
five
time
six
time
case
amplifi
solut
ad
addit
substrat
solut
incub
room
temperatur
min
respect
substrat
solut
ad
incub
room
temperatur
min
min
stop
solut
ad
plate
read
od
nm
within
min
acr
assess
grade
tbb
specimen
experienc
pathologist
use
standard
intern
societi
heart
lung
transplant
ishlt
nomenclatur
grade
acr
grade
b
acr
consid
episod
clinic
suspect
acr
antibodymedi
reject
amr
clad
includ
analysi
specimen
classifi
infect
bal
fluid
microbiolog
studi
identifi
bacteria
viral
pathogen
fungi
mycobacteria
bacteri
cultur
consid
posit
cultur
show
growth
greater
viabl
organ
per
ml
exclud
oral
flora
pcr
use
detect
respiratori
virus
adenoviru
bocaviru
coronaviru
enteroviru
influenza
influenza
b
metapneumoviru
parainfluenzaviru
parechoviru
rhinoviru
rsv
cmv
cultur
result
includ
analysi
studi
includ
clinic
present
radiolog
find
macroscop
appear
bal
fluid
concomit
antibiot
antivir
antifung
treatment
bronchoscopi
sampl
classifi
patholog
process
tbb
bal
fluid
microbiolog
studi
show
patholog
process
irrespect
clinic
radiolog
present
statist
analysi
perform
r
version
r
foundat
statist
comput
vienna
austria
use
proc
broom
lmertest
surviv
librari
baselin
recipi
characterist
express
mean
standard
deviat
median
interquartil
rang
continu
variabl
frequenc
percentag
categor
variabl
cytokin
concentr
log
transform
prior
analysi
ensur
normal
distribut
concentr
low
detect
elisa
assay
assign
valu
pgml
boxplot
gener
use
default
set
r
graphic
librari
whisker
default
time
interquartil
rang
continu
variabl
compar
use
mannwhitneyu
test
kruskalw
test
categor
variabl
compar
use
fisher
exact
test
multivari
analysi
control
patient
characterist
frequent
associ
reject
includ
age
underli
lung
diseas
type
infect
bacteri
viral
fungal
roc
curv
four
cytokin
calcul
use
proc
packag
overal
surviv
ltr
assess
use
kaplanmei
method
compar
use
logrank
test
censor
decemb
acr
statu
assess
transplant
consid
timevari
covari
part
analysi
reshap
data
accordingli
studi
period
februari
novemb
subject
underw
lung
transplant
subject
exclud
cytokin
data
record
patient
health
record
system
andor
bronchoscopi
perform
remain
subject
bal
fluid
sampl
analyz
compar
tbb
specimen
obtain
bronchoscopi
median
number
tbb
bal
sampl
per
patient
iqr
median
time
first
tbb
sampl
iqr
day
patient
characterist
provid
tabl
compar
ishlt
thorac
transplant
registri
data
studi
popul
includ
greater
proport
patient
receiv
transplant
cf
vs
pulmonari
fibrosi
vs
convers
patient
includ
studi
receiv
slightli
fewer
transplant
chronic
obstruct
pulmonari
diseas
copd
vs
pulmonari
hypertens
vs
overal
total
patient
experienc
least
one
episod
acr
first
year
post
transplant
vs
ishlt
bronchoscopi
result
group
base
microbiolog
patholog
analys
bronchoscopi
specimen
show
patholog
process
remain
sampl
show
acr
infect
combin
acr
infect
tabl
provid
overview
cytokin
concentr
differ
group
fig
show
level
log
among
four
subgroup
signific
differ
observ
also
show
signific
differ
specif
group
shown
fig
none
cytokin
optim
cutoff
diagnos
combin
acr
infect
isol
episod
acr
depend
guidelin
differ
transplant
center
acr
may
treat
acr
episod
level
log
acr
median
vs
differ
combin
acr
viral
bacteri
fungal
infect
patholog
process
combin
acr
infect
shown
boxandwhisk
plot
signific
differ
specif
group
determin
use
kruskalw
test
signific
differ
two
categori
determin
use
wilcoxon
rank
sum
test
log
level
lowest
acr
highest
combin
acr
infect
compar
patholog
process
p
p
respect
infect
median
vs
acr
defin
oppos
acr
p
differ
observ
level
log
log
log
p
p
p
respect
use
linear
mix
effect
model
found
signific
differ
cytokin
level
specif
group
cytokin
adjust
age
underli
diseas
lead
lung
transplant
type
infect
time
surveil
bronchoscopi
show
significantli
lower
log
level
patient
infect
patient
patholog
process
p
also
log
lower
patient
acr
patholog
process
p
log
acr
p
infect
p
combin
acr
infect
p
patholog
process
log
acr
p
infect
p
combin
acr
infect
p
patholog
process
vari
signific
manner
specif
group
acr
detect
tbb
sampl
show
acr
patient
experienc
one
event
acr
first
year
transplant
patient
experienc
two
event
patient
experienc
two
event
accord
surveil
bronchoscopi
use
gener
linear
mix
model
acr
decreas
slightli
first
year
odd
ratio
per
month
p
differ
rate
acr
event
observ
type
pathogen
detect
surveil
bronchoscopi
bacteri
infect
p
viral
infect
p
fungal
infect
p
among
patient
undergo
surveil
bronchoscopi
tbb
eight
die
within
first
year
transplant
median
condit
surviv
year
patient
without
acr
year
patient
minimum
one
biopsyproven
acr
first
year
transplant
respect
shown
fig
surviv
rate
similar
patient
without
episod
acr
higher
compar
ishlt
registri
data
era
june
signific
differ
overal
surviv
patient
without
acr
hazard
ratio
confid
interv
p
among
patient
acr
grade
acr
grade
acr
hazard
ratio
confid
interv
p
correl
acr
event
per
patient
surviv
p
optim
cutoff
deriv
data
right
roc
curv
diagnos
combin
acr
infect
surveil
bronchoscopi
tbb
first
year
transplant
area
curv
area
curv
optim
cutoff
deriv
data
particularli
higher
score
appear
correspond
higher
probabl
combin
acr
infect
observ
studi
could
detect
relev
role
bal
fluid
sampl
ltr
identifi
complic
includ
acr
infect
adjust
age
underli
diseas
lead
lung
transplant
type
infect
time
surveil
bronchoscopi
minor
differ
cytokin
level
observ
data
show
pattern
bal
cytokin
minor
valu
diagnost
marker
ltr
report
data
role
acr
conflict
wherea
experiment
clinic
data
show
signific
increas
acr
studi
found
signific
associ
despit
high
number
sampl
correl
found
analys
significantli
lower
infect
ltr
patholog
process
adjust
age
underli
diseas
type
infect
correl
found
acr
along
line
previou
studi
link
develop
clad
role
detect
acr
seem
neglig
accord
data
level
significantli
lower
acr
correct
age
underli
diseas
type
infect
howev
light
result
previou
studi
find
interpret
caution
level
correl
four
prespecifi
group
accordingli
previou
studi
suggest
correl
acr
technic
note
elisa
best
method
detect
sinc
limit
detect
cytokin
activ
membran
bound
form
surviv
differ
patient
acr
acr
differ
seen
patient
multipl
acr
event
howev
includ
data
obtain
surveil
bronchoscopi
without
clinic
sign
allograft
dysfunct
patient
follow
everi
week
within
first
six
month
follow
transplant
week
thereaft
center
due
limit
size
switzerland
clinic
sign
infect
allograft
reject
prompt
immedi
treatment
addit
patient
multipl
acr
event
earli
sign
clad
treat
extracorpor
photophoresi
potenti
explain
higher
surviv
rate
compar
data
ishlt
registri
summari
correl
found
cytokin
studi
surviv
patient
suggest
cytokin
suitabl
marker
monitor
studi
sever
limit
first
retrospect
studi
thu
even
though
plan
surveil
bronchoscopi
regular
interv
select
bia
ca
nt
exclud
patient
clinic
relev
allograft
dysfunct
infect
undergo
surveil
bronchoscopi
might
explain
deriv
data
patient
miss
potenti
subject
also
obtain
total
cell
count
bal
sampl
includ
inform
analysi
increas
total
cell
count
nonspecif
lung
transplant
also
found
period
infect
reject
second
restrict
cytokin
analysi
small
number
cytokin
studi
initi
commerci
avail
valid
kit
use
center
four
cytokin
associ
reject
previou
studi
also
perform
immunolog
analys
reflect
innat
immun
system
alpha
defensin
matrix
metalloproteinas
combin
bal
cytokin
cytolog
level
might
contribut
composit
score
increas
diagnost
accuraci
bal
diagnos
acr
howev
evalu
score
part
studi
third
due
fact
amr
illdefin
condit
public
ishlt
consensu
report
includ
patient
amr
studi
fourth
perform
analys
associ
cytokin
clad
develop
diagnosi
clad
indic
treat
patient
immunomodulatori
macrolid
even
absolut
number
patient
receiv
macrolid
institut
first
year
lung
transplant
low
bia
treatment
cytokin
distribut
bal
exclud
fifth
statist
method
use
adjust
storag
time
bal
sampl
number
analys
per
patient
date
collect
transplant
sixth
infect
defin
base
microbiolog
find
bal
fluid
take
account
clinic
symptom
imag
studi
macroscop
appear
bal
fluid
concomit
antibiot
antivir
antifung
medic
detect
infect
differenti
infect
acr
base
clinic
symptom
may
difficult
ltr
thu
patient
multipl
immunosuppress
drug
mere
presenc
pathogen
bal
fluid
absenc
clinic
deterior
may
fulfil
criteria
infect
prompt
antiinfect
treatment
inde
center
pathogen
find
bal
fluid
except
oral
flora
candida
speci
prompt
antiinfect
treatment
aspect
immunolog
analysi
warrant
discuss
centrifug
bal
specimen
recent
intern
review
conduct
immunolog
lab
compar
cytokin
concentr
bal
sampl
without
prior
centrifug
differ
seen
major
sampl
unpublish
data
measur
bal
cytokin
level
week
therefor
necessarili
day
obtain
final
bal
fluid
sampl
store
process
maximum
one
week
intern
analysi
perform
immunolog
lab
show
differ
cytokin
concentr
bal
sampl
store
sampl
store
immedi
arriv
process
one
week
later
need
standard
bal
techniqu
ltr
ishlt
recent
establish
work
group
address
issu
far
bal
procedur
concern
quotient
instil
volum
aspir
volum
calcul
provid
facilit
compar
cellular
protein
concentr
studi
would
particularli
import
cytokin
concentr
typic
low
correct
dilut
factor
bal
fluid
urea
method
describ
wherebi
measur
bal
fluid
cytokin
concentr
adjust
urea
plasma
bal
coeffici
appli
method
studi
normal
data
levi
colleagu
recent
show
sequenti
bal
sampl
reflect
distinct
pulmonari
compart
might
implic
futur
research
along
line
center
agre
standard
cytokin
detect
method
compar
method
low
elisa
reliabl
method
center
howev
costli
requir
strict
adher
time
protocol
fac
assay
may
altern
select
cytokin
yet
method
yield
less
reliabl
result
laboratori
also
numer
potenti
confound
relat
medic
dosag
immunosuppress
antiinfect
prophylaxi
treatment
addit
individu
medic
immunolog
analysi
make
interpret
cytokin
data
ltr
challeng
field
rheumatolog
attempt
made
harmon
autoantibodi
nomenclatur
therebi
optim
antinuclear
antibodi
usag
base
data
shown
identif
singl
biomark
profil
differ
biomark
unlik
provid
conclus
lung
allograft
function
whether
comput
algorithm
precis
medicin
might
help
translat
complex
data
clinic
set
unclear
moment
opinion
achiev
collabor
approach
use
standard
valid
method
larg
prospect
multicent
cohort
studi
effort
crucial
howev
optim
surviv
qualiti
life
ltr
summari
one
largest
retrospect
studi
analyz
bal
fluid
cytokin
profil
ltr
cytokin
investig
role
diagnos
complic
lung
transplant
unlik
attempt
studi
bal
fluid
cytokin
context
acr
infect
ltr
add
novel
valuabl
insight
ne
conduct
data
collect
statist
analysi
provid
draft
version
revis
manuscript
ep
supervis
laboratori
analys
review
version
manuscript
assist
write
final
version
sh
perform
statist
analysi
assist
write
final
version
cb
mk
review
version
manuscript
assist
write
final
version
lch
design
project
revis
version
manuscript
assist
write
final
version
car
design
supervis
project
revis
version
manuscript
provid
final
version
author
read
approv
final
manuscript
studi
partial
fund
lung
author
conflict
interest
disclos
work
support
grant
lung
grant
number
ne
conduct
data
collect
statist
analysi
provid
draft
version
revis
manuscript
ep
supervis
laboratori
analys
review
version
manuscript
assist
write
final
version
sh
perform
statist
analysi
assist
write
final
version
cb
mk
review
version
manuscript
assist
write
final
version
lch
design
project
revis
version
manuscript
assist
write
final
version
car
design
supervis
project
revis
version
manuscript
provid
final
version
author
read
approv
final
manuscript
